Alexander Müller

Gesundheitsinnovator 🚀 | KI-Enthusiast 🤖 | Marathonläufer 🏃‍♂️

[ERS @EuroRespSoc]

🎥 Watch the replay of yesterday’s webinar ‘Panel discussion – Endotype-specific therapy for improving patient-centred outcomes’ – available now on the ERS Respiratory Channel: https://t.co/8SGDSk4DCE

[OncLive.com @OncLive]

🤖 "The next generation needs to understand that they will need to find a way to complete rather than compete with AI," said @RLRandallMD of @UCD_Cancer on how AI may affect oncology training, how to properly work alongside AI, and AI-patient conversations.

Full conversation ➡️: https://t.co/AWIU6els5H

#AI #oncology

[Vivek Subbiah, MD @VivekSubbiah]

⭐️Delivering Precision Oncology at Scale-Infrastructure, Evidence, and the Path Forward @JAMAOnc @OncoAlert @oncodaily https://t.co/7jOIKNVte4

[Hilly Paige Jr @hillypaige2]

#KnowFH
#FHAwarenessDay

@FamilyHeartFdn @fhpatienteurope @ASPCardio @nationallipid @CiccaroneCenter @NorthwellHealth @BNordestgaard @SethJBaumMD @SethShayMartin @aafp @AANP_NEWS @AAPAorg @HeartNurses @advcardiohealth @AmerAcadPeds @PriMedCME

[Ash Paul @pash22]

The Vanishing Advantage of Specialization: AI, Knowledge Utilization, and the Boundary of the
Firm
https://t.co/IxqSULtfzD via @lugaricano

[MAX @maxxmalist]

The race for AGI

Script: Sherpa by Pocket FM
Video: Seedance 2.5

[Elvina Almuradova @Dr_ElvinaA]

Phase 3 BCTOP trial in HER2+ early breast cancer:
Neoadjuvant anbenitamab + HB1801 achieved higher tpCR vs trastuzumab + pertuzumab + docetaxel:
• tpCR: 62.4% vs 51.2%
• Δ +11.4%, P=.004
• G3–4 TRAEs: 29.3% vs 28.3%
@Larvol @OncoAlert

[Joshua Richter, MD, FACP @JoshuaRichterMD]

Samir Parekh giving a master class on: Immune markers of disease activity At #IMS26 #mmsm @TischCancer @Myeloma_Society

[Joshua Richter, MD, FACP @JoshuaRichterMD]

Zach Avigan with a groundbreaking presentation at #IMS26. #mmsm @TischCancer @Myeloma_Society : MRD depth by NGS and distinct clonotypic patterns below the
limit of detection predict divergent relapse risk after sustained
remission

[STAT @statnews]

“The epidemiology and genetics of heart attack and stroke risk, for now, seem to have outpaced what more we can actually do about it,” writes cardiologist Vishal Khetpal. https://t.co/wqW7VjqVbS

[KFF Health News @KFFHealthNews]

The number of nursing homes has fallen by nearly 900 in the last decade. Low Medicaid reimbursements and staff pay challenge their survival amid the growth of alternatives.
https://t.co/XAUWLpZdWu

[Gavi, the Vaccine Alliance @gavi]

Nepal’s flood was the first emergency. Now comes the risk of another.

Contaminated water, crowded shelters and damaged health facilities are raising concerns about infectious disease outbreaks with health teams racing to respond.

Here’s a look at the current response on the ground in Nepal: https://t.co/NnSH7Y3em6

[Stephen V Liu, MD @StephenVLiu]

Early results from REACH-EGFR trial of VRN110755, a mutant selective EGFR TKI, at #WCLC26 show activity in EGFR C797S (6/6 responses) with ctDNA clearance and early signs of intracranial efficacy. Most common TRAE was rash but no discontinuations due to TRAE in 67 pts.

[Stephen V Liu, MD @StephenVLiu]

Rapid fire discussion on #WCLC26 with global oncology colleagues Drs. @LauraAlderMD @TejasPatilMD @ChandrakanthMv @QuantumOnc @ullas_batra @g_mountzios led by @SuyogCancer - always appreciate the different perspectives everyone brings to the emerging data.

[OncoDaily @oncodaily]

Heading to New York to Join the IAPM at UNGA 2026 - @VivekSubbiah

@united4cancer

https://t.co/tGWWePOi9m

[Ramesh Dontha 🦉 @EntrepreneursAI]

AIHealthTech Insider: An AI virtual cell tested 100+ cancer treatments before touching a single patient. Published in Nature.

→ ProteinTalks: tracks how 38 million protein measurements change over time after drugs are applied
→ Tested 63 FDA-approved anticancer drugs + 59 two-drug combinations on breast cancer cells
→ Measured response at 6, 24, and 48 hours — not a single snapshot
→ Predicted drug effectiveness, found new combinations, identified resistance proteins
→ Ranked treatments including repurposed drugs that showed activity in lab-grown tumor organoids

Most AI models see cells as a snapshot. This one watches them change over time. That's the difference. https://t.co/Pg4vmGo6UI

[Euro-BioImaging ERIC @EuroBioImaging]

#VirtualPub We are delighted to welcome Simone Mattei, EMBL Imaging Centre, for a talk on "Targeted cryo-Serial Lift Out for cellular structural biology." 
🗓️ Friday, September 25 @ 13:00 CEST
Register⤵️
https://t.co/TbiCKAPwKX

[Colin Hung @Colin_Hung]

As healthcare data and images grow, AI agents could coordinate entire workflows—not just individual tasks.

NVIDIA and Dell Technologies discuss what that could mean for healthcare. 👀

Check it out: https://t.co/dK4zrM5SbS

@DellTechHealth @NVIDIA #HealthcareAI #healthtech

[Clinical Cancer Research @CCR_AACR]

Dr. Nina Steele, recipient of the 2026 Clinical Cancer Research Early Career Award, talks about the translational opportunities she's most excited about in relation to her study. Watch the full interview: https://t.co/1UEac7SiPN @NinaSteele17 @uofcincycancer @UCincyMedicine

[OncLive.com @OncLive]

Sequencing decisions in advanced/metastatic GIST carry real consequences for outcomes and quality of life — and the data behind those decisions keeps shifting. Don't miss our expert-led session: we'll dig into disease biology, treatment sequencing and safety profiles, and the latest trial data redefining care!

📅 October 6 | 🕕 6:30 PM ET 

Save your spot: https://t.co/eWOq4KUdZe    
#GIST #Oncology #AsktheExpert